Concomitant use of diuretics and SGLT2i in HF
Video navigation menu
- Mechanistic study of 14 days 01:39
- Mechanistic study of 6 weeks 04:12
- Analyses of Emperor-Reduced and DAPA-HF 06:06
- Conclusions 09:47
This presentation was broadcasted at the e-SPACE CRM conference, a global web-conference on the cardio-renal-metabolic syndrome, that was held January 22-24, 2021.
The post hoc analysis of DAPA-HF on the effect of SGLT2i on risk of hyperkalemia associated with MRA use in HFrEF has now been published.
Prof. Patrick Rossignol, MD - Professor of Therapeutics at the University of Lorraine, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.